Quality Assurance and Preventing Serious Adverse Events in the Home Hemodialysis Setting

Keigan M. More, Karthik Tennankore

Résultat de recherche: Review articleexamen par les pairs

3 Citations (Scopus)

Résumé

Patient safety is of the utmost importance in home hemodialysis (HHD). Recognizing that there are risks related to vascular access (both infectious and noninfectious events), dialysis water quality, and procedural-related adverse events (including arteriovenous fistula needle dislodgement or air embolism), there is a need for systematic identification and management. Although adverse events are relatively infrequent in HHD, the potential consequences of these events may include significant morbidity, HHD treatment failure, or death. Therefore, having a systematic framework to review each event, audit and retrain patient technique, disclose and discuss events with patients, home unit staff and device companies (if relevant) and determine preventative measures to avoid future adverse events, is crucial. In this review, we will describe the literature around the types and relative frequency of serious adverse events in the HHD setting and we will outline a quality assurance framework for capturing, managing, and avoiding serious adverse events. Finally, we will describe some of the novel existing approaches to preventing or addressing serious adverse events and critical knowledge gaps that should be evaluated in future study.

Langue d'origineEnglish
Pages (de-à)170-177
Nombre de pages8
JournalAdvances in Chronic Kidney Disease
Volume28
Numéro de publication2
DOI
Statut de publicationPublished - mars 2021

Note bibliographique

Funding Information:
Financial Disclosure: The authors declare that they have no relevant financial interests. Support: K.T. has received investigator-initiated grant support from Astellas, Otsuka, and Baxter. He has conducted consulting work/Advisory Board work for Otsuka, Janssen, Baxter, and AstraZeneca. K.M. has no conflicts to declare.

Funding Information:
Support: K.T. has received investigator-initiated grant support from Astellas, Otsuka, and Baxter. He has conducted consulting work/Advisory Board work for Otsuka, Janssen, Baxter, and AstraZeneca. K.M. has no conflicts to declare.

Publisher Copyright:
© 2021 National Kidney Foundation, Inc.

ASJC Scopus Subject Areas

  • Nephrology

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review

Empreinte numérique

Plonger dans les sujets de recherche 'Quality Assurance and Preventing Serious Adverse Events in the Home Hemodialysis Setting'. Ensemble, ils forment une empreinte numérique unique.

Citer